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Cyclooxygenase (COX) catalyzes the conversion of ara-chidonic acid to prostaglandin H2, which is then further 
metabolized by downstream synthase enzymes to a range of 
eicosanoids. COX is expressed in 2 isoforms, constitutive 
COX-1 and inducible COX-2. Nonsteroidal anti-inflamma-
tory drugs (NSAIDs) are widely used to treat inflammation 
and pain and show potential to prevent cancer. COX-2 is 
the therapeutic target of NSAIDs, although most members 
of this class of drugs inhibit both isoforms of COX1 and, 
as a consequence, are associated with gastrointestinal side 
effects.2 NSAID-induced gastrointestinal side effects are rel-
atively common and can be serious, limiting the use of these 
drugs in some patients and proving fatal in others.3 COX-2 
selective inhibitors such as Vioxx (rofecoxib) and Celebrex 
Background—Cardiovascular side effects associated with cyclooxygenase-2 inhibitor drugs dominate clinical concern. 
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However, the mechanisms linking cyclooxygenase-2 inhibition and cardiovascular events are unknown and no biomarkers 
have been identified.
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(celecoxib) were originally developed to target COX-2 at 
the site of inflammation while sparing COX-1 in the gut 
and so reducing the gastrointestinal side effects typical of 
NSAIDs.4 However, now, cardiovascular side effects associ-
ated with COX-2 inhibition dominate concern over NSAID 
usage5–7 and have stopped the development of new drugs in 
this class. The cardiovascular side effects caused by the inhi-
bition of COX-2 are mainly myocardial infarctions,8,9 which 
implies increased thrombosis and atherosclerosis and have 
been considered to reflect local loss of the cardioprotective 
hormone prostacyclin by blood vessels. However, COX-2 is 
only sparsely detected in blood vessels, where, by contrast, 
COX-1 is readily detected. COX-2 is upregulated at sites of 
vascular inflammation, including atherosclerotic plaques, 
although, even at these areas, COX-1 drives prostacyclin 
release.10 Although COX-2 is largely absent from blood ves-
sels,11–13 there are key areas in the body, including the kid-
ney,14–17 where it is expressed constitutively. COX-2 in the 
kidney regulates natriuresis, diuresis, and vasodilation.16–18 
NSAIDs, including COX-2 selective drugs, therefore have 
well-documented effects on the kidney and increase blood 
pressure by ≈1 to 2 mm Hg in normotensive individuals and 
by up to 14 mm Hg in patients with hypertension.19 In addi-
tion, they are known to dysregulate glomerular filtration and 
salt/water homeostasis.20–23 Given the well-established link 
between impaired renal function and cardiovascular events, 
including myocardial infarctions, it is logical to expect that 
these changes in renal function may contribute to the car-
diovascular side effects associated with NSAID usage.24 
However, the precise mechanism by which COX-2 regulates 
renal function and the relevance of COX-2 in the kidney in 
comparison with other cardiovascular tissues are not known, 
and the debate continues regarding the relative contribution 
of vascular prostacyclin versus renal effects to cardiovas-
cular side effects of NSAIDs.25 Consequently, there are no 
biomarkers of NSAID-induced cardiovascular risk and no 
avenues to protect those that might be more susceptible than 
the general population.
To address this issue, we have performed a transcriptomic 
analysis of the 4 key cardiovascular tissues, kidney, heart, 
aorta, and blood, from wild-type and COX-2–deficient mice. 
Pathway analysis revealed alterations in the kidney of genes 
associated with nitric oxide (NO) biology, particularly those 
regulating the synthesis and metabolism of the endogenous 
NO synthase (NOS) inhibitors asymmetrical dimethylargi-
nine (ADMA) and monomethyl-l-arginine (l-NMMA). We 
went on to validate increased ADMA and l-NMMA levels 
in plasma of mice lacking COX-2 and in wild-type mice or 
healthy human volunteers taking COX-2 selective inhibitors. 
Our work fits well with and helps to explain recent observa-
tions showing that endothelial NO synthase (eNOS) responses 
are reduced in vessels from COX-2–deficient mice.26 Because 
NO release from endothelial cells performs the same protec-
tive role that prostacyclin performs on platelets and blood 
vessels, and because it synergizes powerfully with prostacy-
clin in platelets,27 our observations are the first to provide a 
rational explanation for how the inhibition of COX-2 in the 
kidney can remotely regulate vascular side effects throughout 
the vasculature.
Methods
Experimental Animals
Male or female COX-1–/– and COX-2–/– mice,11 back-crossed for >7 
generations onto a C57Bl/6J background (Harlan, UK) were used at 
10 to 12 weeks of age. For transcriptomic studies, littermate COX-
2+/+ mice from COX-2–/– colonies were used. For other studies, wild-
type mice maintained separately were used as controls. Animals 
were genotyped before use.11 Mice lacking prostacyclin receptors 
(IP–/–), supplied by Dr Rolf Nüsing, were on a C57BL/6 background 
as described.28 Animal studies were conducted in accordance with 
Animals (Scientific Procedures) Act 1986, which is a UK act after 
local ethical review.
Pharmacological COX-2 Inhibition and Blood 
Pressure Measurement
Parecoxib (Pfizer, USA; 100 mg·kg–1·d–1) in drinking water was 
administered for 4 days to wild-type mice. Mean carotid arterial 
blood pressure was measured by using radiotelemetry. In brief, a 1.4F 
Millar MikroTip pressure catheter was inserted in the right common 
carotid artery of spontaneously breathing mice anesthetized with 
inhaled isoflurane (Abbott, USA). Animals were allowed to recover 
from the anesthetic, and measurements were made in conscious, unre-
strained animals 21 days later. Blood pressure traces were recorded 
continuously with the use of the PowerLab and Chart 5 software (AD 
Instruments Ltd, UK). Blood was obtained by tail nick in conscious 
animals into 3.2% citrate and plasma separated by centrifugation.
Mouse Tissue Collection and Processing
Mice were euthanized by CO2 narcosis. Blood collected from the 
inferior vena cava into heparin (10 U/mL final; Leo Laboratories, 
UK) or clotting-tubes (Sarstdet, UK) was centrifuged for serum/
plasma. Urine was collected by amniocentesis. Serum urea was 
measured by a commercial veterinary diagnostics service (IDEXX 
Laboratories, UK).
Microarray Analysis
Tissues were snap frozen and homogenized, and total RNA was 
extracted by using a silica column–based kit (Nucleospin RNA II; 
Machery-Nagal, UK). Samples were converted to cDNA, frag-
mented, labeled, and hybridized to MouseRef-8v3 BeadChip arrays 
(Illumina, UK). Data were quantile normalized and analyzed by 
using the linear models for microarray data modified t test method 
and Benjamini-Hochberg false discovery rate correction by using 
GeneSpring GX 12.1 software (Agilent, USA). Differential expressed 
genes with a corrected P value of q<0.05 were considered statistically 
significant. Focused pathway analysis was performed by examina-
tion of genes altered >1.3-fold (q<0.05) featuring in the following 
human Gene Ontology (http://www.geneontology.org) pathways: 
(1) regulation of systemic arterial blood pressure (GO:0003073); 
(2) regulation of blood vessel size (GO:0050880); (3) NO biosyn-
thetic process (GO:0006809); (4) prostaglandin biosynthetic pro-
cess (GO:0001516); (5) regulation of angiotensin levels in blood 
(GO:0002002); (6) endothelin maturation (GO:0034959); (7) epi-
nephrine biosynthetic process (GO:0042418); and (8) protein-argi-
nine N-methyltransferase activity (GO:0090627).
Real-Time Quantitaive Polymerase Chain Reaction
RNA was converted to cDNA using the iScript cDNA synthesis kit 
(BioRad, CA, USA). Quantitative polymerase chain reaction was per-
formed using a 7500 Fast Real-time polymerase chain reaction system 
(Applied Biosystem). Ddah1 (5′-CACAGAAGGCCCTCAAGATCA-3′, 
5′-TCTCATAGACCTTTGCGCTTTC-3′), Ddah2 (5′-CCTGGTGCCA 
CACCTTTCC-3′, 5′-AGGGTGACATCAGAGAGCTTCTG-3′) and 
Agxt2 (5′-GGCTTCCCCATGGCTGCAGTT-3′, 5′-CAATCACCTCA 
AGCACAGCAGATCC-3′). mRNA levels were  determined bus-
ing the iTAQ fast SybrGreen supermix with ROX (BioRad, 
CA, USA) expression assays and normalized to levels of Actb 
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(5′-CCAGGGTGTGATGGTGGGAATG-3′, 5′-CGCACGATTTCCC 
TCTCAGCTG-3′). For Ptgs2 (probe ID: Mm00478374_m1), Prmt1 
(probe ID: Mm00480133_m1), Arg1 (probe ID: Mm00475988_
m1), Arg2 (probe ID: Mm00477592_m1), 18S rRNA (probe ID: 
Mm03928990_g1), and Gapdh (probe ID: Mm99999915_g1) gene 
expression levels were determined using TaqMan expression assays. 
Genes were quantified relative to housekeeping genes (Actb or 
Gapdh/18S) by comparative Ct methods.
Liquid-Chromatography Tandem Mass-
Spectrometry Measurements
Samples were analyzed as described previously29 with a Agilent 
6400 series triple quadruple liquid-chromatography tandem mass-
spectrometry using mobile phase (0.1% formic acid, 1% acetoni-
trile). The mass spectrum parameters for detection were as follows: 
ADMA, mass-to-charge ratio (m/z): 203.3 to 46.0, collision energy: 
12; symmetrical dimethylarginine (SDMA), m/z: 203.3 to 70.2, colli-
sion energy: 24; l-NMMA, m/z: 189.3 to 70.2, collision energy: 24; 
d7-ADMA, m/z: 210.0 to 46.0, collision energy: 24. Concentrations 
of individual amino acids, l-NMMA, ADMA, SDMA, or creatinine 
were calculated from standard curves generated by using authentic 
standards.
Vasomotor Responses
Mice were euthanized by CO2 narcosis, and the thoracic aorta was cut 
into 2-mm aortic rings, mounted in organ baths of a Mulvany-Halpern 
myograph at a resting tension of 13 kPa in Krebs with or without 
l-arginine (100 μmol/L; Sigma, UK) and contracted with of endothe-
lin (ET)-1 (30 pmol/L to 30 nmol/L; Sigma, UK) or the thromboxane 
mimetic U46619 (1 nmol/L to 1 μmol/L). After washing, tissues were 
contracted with an EC80 concentration of U46619 (30–100 nmol/L) 
followed by acetylcholine (1 nmol/L to 10 μmol/L) or sodium nitro-
prusside (SNP; 1 pmol/L to 10 μmol/L). For ET-1 studies, vessels 
were preincubated with the NOS inhibitor NG-nitro-l-arginine methyl 
ester (100 μmol/L; Sigma, UK) to exclude any effect of changes in 
the NO/ADMA pathway. Force was recorded via a PowerLab/800 
(AD Instruments Ltd., UK) and analyzed by using Chart 6.0 acquisi-
tion system (AD Instruments Ltd, UK).
Clinical Study
Sixteen healthy young male volunteers aged 20 to 35 who had 
abstained from NSAID use for 14 days previously were recruited. 
Volunteers received standard doses of the COX-2 selective 
inhibitor Celebrex (celecoxib; 200 mg twice a day; Pfizer USA), or 
the nonselective COX-1/COX-2 inhibitor Naprosyn (naproxen; 500 
mg twice a day; Roche Switzerland) for 7 days. After overnight 
fasting, on day 0, before the first dose, and day 7, 2 hours after 
the final dose, blood was collected into citrate Vacutainers (BD 
Diagnostics, UK) and separated by centrifugation. This study was 
approved by the St Thomas’s Hospital Research Ethics Committee 
(Ref. 07/Q0702/24) and conducted according to the Declaration 
of Helsinki. All volunteers gave written informed consent before 
entering the study.
Statistical Methods
Data are mean±standard error of the mean. Statistical significance 
(taken as P<0.05) was determined by using the following tests: 
Mann–Whitney (1 variable, 2 groups), Wilcoxon signed-rank (1 vari-
able, 2 paired groups), Kruskal–Wallis with the Dunn post hoc test 
(1 variable, 3 groups), or Quades test (2 variables). All tests were 
performed using GraphPad Prism 6 software, with the exception of 
the Quades test, which was performed using R. Significance was 
assumed where P<0.05. No further correction has been made for mul-
tiple testing (typically <5 end points per animal). The exception is 
analysis of transcriptomic data where false discovery rate correction 
has been applied as described above.
Results
Expression of COX-2 in the Kidney
As others have shown,16 constitutive expression of Ptgs2 
gene, which encodes the COX-2 protein, was seen in the 
medulla region of the kidney, with lower levels in the cor-
tex (Figure 1A), which others have shown is relatively sparse 
unless animals are salt depleted.16 As seen by others, the 
loss of COX-2, but not of COX-1, resulted in renal compro-
mise associated with increased serum urea and creatinine30 
(Figure 1B and 1C).
Effect of COX-2 on the Transcriptome in 
Cardiovascular Tissues
In the blood, heart, and aorta, COX-1 activity drives pros-
tanoid production with little or no contribution from COX-
2.11,14 Consistent with this, no genes were altered by COX-2 
Figure 1. Renal COX-2 expression and effects on 
renal function. A, Expression of COX-2 in the aorta, 
renal cortex, and renal medulla of wild-type mice. 
Changes in levels of serum urea (B) and serum 
creatinine (C) in wild-type, COX-1–/–, and COX-2–/– 
mice. Data are mean±SEM for n=8 to 14 mice in 
each group. P values by Kruskal–Wallis with the 
Dunn post hoc test. COX indicates cyclooxygenase; 
and SEM, standard error of the mean.
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deletion in the blood of COX-2–/– mice, and, in the heart and 
aorta, only 1 gene was altered/decreased, Rgl1, in both tissues 
(Table I in the online-only Data Supplement). By contrast, in 
the renal medulla, deletion of COX-2 altered the expression 
of 1018 genes by >1.5-fold (Figure 2A; Table I in the online-
only Data Supplement). To explore the consequences of this 
finding, we applied focused pathway analysis to specifically 
examine changes in (1) blood pressure control, (2) vascular 
tone, and (3) vascular hormones and identified alterations in 
the expression of a number of genes involved in angioten-
sin, ET, and NO (Figure 2B). Changes in angiotensin genes 
(Anpep, Agt, Mme) were predictive of reduced activity, so 
they were unlikely to be implicated in the deleterious effects 
of COX-2 inhibitors. ET-1 and ET receptor gene expression 
(Edn1, Endra, Ednrb) was increased (Figure 2B). However, 
levels of ET-1 in the plasma of COX-2–/– mice were not altered 
(Figure IA in the online-only Data Supplement). Moreover, 
contractile responses in the aorta to ET-1 were not signifi-
cantly altered in COX-2–/– mice (Figure IB in the online-only 
Data Supplement). We therefore focused on a cluster of genes 
(Agxt2, Ddah2, Prmt1) related to the turnover of methylargi-
nines such as ADMA and l-NMMA, which are inhibitors of 
NOS enzymes. Using quantitative polymerase chain reaction, 
we confirmed that in COX-2–/– renal medulla expression of 
Prmt1 (Figure 2C), which drives methylarginine synthesis,29 
was increased; Ddah2, which breaks down methylarginine, 
was nonsignificantly increased (Figure II in the online-only 
Data Supplement), whereas Agxt2, which degrades methylar-
ginines,29 tended to be reduced (Figure 2D). Using quantita-
tive polymerase chain reaction , we also observed reduced 
expression of Ddah1, which, like Agxt2, is responsible for 
methylarginine breakdown29 (Figure 2E).
Effect of COX-2 on Plasma Methylarginines and 
eNOS Responses in Mouse Aorta
Plasma levels of ADMA and l-NMMA were increased in 
COX-2–/–, but not COX-1–/– mice (Figure 3A and 3B). Plasma 
SDMA levels were not changed in COX-2–/– mice (Table II in 
the online-only Data Supplement). Arginases, like NOS, use 
l-arginine as a substrate and can be altered in inflammatory con-
ditions. However, in the renal medulla, Arg1 was not expressed 
and Arg2 was not altered in COX-2–/– mice (Figure IIIA in the 
online-only Data Supplement). In addition, in the aorta, Arg2 
was not expressed in and Arg1 was not altered in COX-2–/– mice 
Figure 2. Transcriptome profiling in 
cardiovascular tissues from COX-2–/– 
mice. A, Number of genes altered in the 
transcriptome of blood, heart, aorta, 
and kidney (renal medulla) by >1.2- to 
>3-fold. B, Focused pathway analysis of 
genes altered >1.3-fold (q<0.05). qPCR 
validation of changes in expression of 
Prmt1 (C), Agxt2 (D), and Ddah1 (E) 
in the renal medulla of COX-2–/– mice. 
Data are from n=7 to 8 mice. Data in C 
through E are mean±SEM. P values by 
Mann–Whitney U test. COX indicates 
cyclooxygenase; qPCR, quantitative 
polymerase chain reaction; and SEM, 
standard error of the mean.
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(Figure IIIB in the online-only Data Supplement). In line with 
this finding, l-arginine was not significantly altered in COX-
2–/– mice (Figure IIIC in the online-only Data Supplement), 
resulting in ADMA:l-arginine (Figure IIID in the online-only 
Data Supplement) and l-NMMA:l-arginine (Figure IIIE in 
the online-only Data Supplement) ratios being increased. In 
agreement with these data, the pharmacological inhibition of 
COX-2 in wild-type mice with parecoxib (100 mg/kg for 4 
days) blocked diurnal blood pressure decline (Figure 4A) and 
plasma ADMA (Figure 4B) and l-NMMA levels (Figure 4C), 
as well. l-Arginine levels (Figure IVA in the online-only Data 
Supplement) along with ADMA:l-arginine (Figure IVB in 
the online-only Data Supplement) and l-NMMA:l-arginine 
(Figure IVC in the online-only Data Supplement) ratios were 
increased by parecoxib.
Increased plasma levels of methylarginines are associated 
in other models with reduced eNOS activity in vessels ex 
vivo31 and hypertension in vivo. Aorta from COX-2–/– mice 
had a reduced eNOS response to acetylcholine (Figure 5A). 
However, their response to the NO-donor SNP that relaxes 
vessels via NO independently of the endothelium was not 
altered (Figure 5B), nor was their contractile response to 
U46619 (Figure V in the online-only Data Supplement). 
The reduced eNOS responses in the aorta of COX-2–/– mice 
were reversed in the presence of l-arginine (100 μmol/L; 
Figure 5C). No effect of l-arginine (Figure 5D) was seen on 
response to SNP. These effects were not due to local changes 
in aortic Nos3, Ddah1, Ddah2, or Agxt2 gene expression 
(Figure VI in the online-only Data Supplement).
Effect of Loss of the Prostacyclin Receptor (IP) on 
Renal Gene Expression and Plasma ADMA Levels
Prostacyclin, which acts via cell surface IP receptors, is 
an important COX-derived mediator in the cardiovascular 
system. To establish the relative role of prostacyclin, in 
comparison with the myriad of other COX products, in our 
study, we performed experiments using IP–/– mice. None of 
our genes of interest (Prmt1, Agxt2, Ddah1, Ddah2, or Arg2) 
were altered in the renal medulla from IP–/– mice (Figure VII 
in the online-only Data Supplement). In line, the increase 
seen in ADMA levels associated with the loss of IP gene 
was, although statistically significant (Figure VIIIA in the 
online-only Data Supplement), minor in magnitude in com-
parison with what we report in COX-2–/– mice (Figure VIIIB 
in the online-only Data Supplement). l-Arginine (Figure 
VIIIC in the online-only Data Supplement) and l-NMMA 
(Figure VIIID in the online-only Data Supplement) lev-
els were decreased, whereas those of SDMA (Table II in 
the online-only Data Supplement) were not affected by 
the loss of IP receptors. These changes may reflect altered 
renal function in IP–/– mice, because creatinine levels were 
elevated in plasma (Figure VIIIE in the online-only Data 
Supplement).
Effect of Inhibition of COX-2 in Healthy Human 
Volunteers
In direct corroboration of our findings in mice, the inhibition 
of COX-2 with standard anti-inflammatory doses of celecoxib 
(200 mg twice a day) for 7 days (n=8) increased ADMA levels 
in healthy human volunteers (Table). Naproxen (500 mg twice 
a day), which inhibits COX-2, but also inhibits COX-1, simi-
larly increased ADMA levels in volunteers taking the drug for 
7 days (n=8; Table).
Discussion
The notion that COX-2 is constitutively expressed in the 
kidney is not new and is, in fact, based on observations 
made as early as 1994,32 well before selective COX-2 
Figure 3. Effect of COX gene deletion ADMA 
and l-NMMA in plasma. Levels of ADMA (A) and 
l-NMMA (B) were increased in the plasma of COX-
2–/– mice, but not in COX-1–/– mice. Data are from 
n=4 and presented as mean±SEM. P values by 
Kruskal–Wallis with the Dunn post hoc test. ADMA 
indicates asymmetrical dimethylarginine; COX, 
cyclooxygenase; l-NMMA, monomethyl-l-arginine; 
and SEM, standard error of the mean.
Figure 4. Effect of parecoxib on blood pressure and 
methylarginines. Effect of parecoxib on mean arterial blood 
pressure (A) and plasma ADMA (B) and l-NMMA (C) levels in 
mice. Data are mean±SEM for n=3 to 7. Data in A were analyzed 
by Quades 2-way ANOVA. Data in B and C were analyzed 
by the Mann–Whitney U test. ADMA indicates asymmetrical 
dimethylarginine; ANOVA, analysis of variance; l-NMMA, 
monomethyl-l-arginine; and SEM, standard error of the mean.
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inhibitors were introduced to the clinic. Similarly, the idea 
that the inhibition of COX-2 in the kidney could explain 
the cardiovascular side effects of NSAIDs has been sug-
gested.18–20 However, this view has been somewhat side-
lined by the idea that vascular COX-2 drives prostacyclin 
throughout the systemic circulation,7 and, until our recent 
studies,14,33 the relative importance of the kidney in compar-
ison with large vessels had not been specifically addressed. 
Using a COX-2 luciferase knock-in mouse, we performed 
an unbiased systems-based analysis of COX-2 expression 
in an extensive panel of organs and tissues in the mouse 
and found that renal COX-2 was localized to an intense hot 
spot in the center of the kidney, aligned to the inner region 
of the renal medulla. Here, we validated our earlier report 
and used polymerase chain reaction to show that the COX-2 
(Ptgs2) gene is highly enriched in the medulla in compari-
son with the renal cortex. This is in line with what is known 
about COX-2 in the kidney, which under normal or high-
salt conditions is predominantly expressed in the medulla 
region, particularly in the interstitial fibroblasts.14,16
Although COX-2 expression and activity are low relative 
to those of COX-1 in other cardiovascular structures, such 
as the heart and major blood vessels, conditional knockout 
mice where either endothelial26 or cardiomyocyte34 COX-2 
is deleted have been used to implicate a role of COX-2 in 
cardiovascular function in these structures; although, in the 
heart, the findings with conditional knockout mice were 
questioned and suggested to be confounded by the non-
specific effects of tamoxifen/cre toxicity.35 Nevertheless, to 
identify the gross effect of COX-2 at these sites in compari-
son with the renal medulla and to identify the novel mech-
anisms of NSAIDs, we investigated the effects of COX-2 
gene deletion on the transcriptome. In line with constitu-
tive COX-2 gene activity that we recently reported,14 we 
found that only 1 gene is altered in the heart and aorta of 
COX-2–/– mice, whereas >600 genes were changed by >1.5-
fold in the renal medulla by COX-2 deletion. Clearly, these 
findings implicate a dominant role for constitutive COX-2 
in the kidney in comparison with the heart or aorta. This 
may suggest that endothelial cells outside large vessels, 
potentially in the renal circulation, mediate the effects pre-
viously reported.26 Because of the large number of genes 
altered in the renal medulla by COX-2 deletion, we chose 
to apply a focused gene pathway analysis of transcripts 
Table.  Plasma Methylarginines In Healthy Volunteers Taking Naproxen or Celecoxib
ADMA, μmol/L l-NMMA, μmol/L SDMA, μmol/L Creatinine (Fold Change)
Control 0.81±0.044 0.30±0.024 0.44±0.063 1.00±0.11
Naproxen 1.01±0.049
(P<0.01)
0.31±0.020
(P=0.84)
0.58±0.049
(P=0.19)
1.51±0.05
(P<0.01)
Control 0.75±0.067 0.29±0.013 0.44±0.049 1.00±0.08
Celecoxib 0.90±0.050
(P=0.05)
0.33±0.025
(P=0.31)
0.51±0.045
(P=0.81)
1.55±0.08
(P<0.01)
Methylarginine (ADMA, l-NMMA, and SDMA) and creatinine levels in the plasma of patients before (control) and after 7 days 
of standard anti-inflammatory dosing with naproxen or celecoxib (n=8). Data are represented as mean±SEM. P values by a 
Wilcoxon signed rank test in comparison with baseline values for each individual. ADMA indicates asymmetrical dimethylarginine; 
l-NMMA, monomethyl-l-arginine; SDMA, symmetrical dimethylarginine; and SEM, standard error of the mean.
Figure 5. Effect of COX-2 gene 
deletion of eNOS responses in aorta. 
Acetylcholine (ACh; A) or sodium 
nitroprusside (SNP; B) induced the 
relaxation of aorta from wild-type and 
COX-2–/– mice. Maximum relaxation 
responses of the aorta from wild-type 
and COX-2–/– mice induced by Ach (C) 
or SNP (D) in the absence or presence 
of l-arginine (100 μmol/L). Data are the 
mean±SEM for n=6 to 10. P values for 
A and C were by Quades 2-way ANOVA 
and for B and D were by Mann–Whitney 
U test. ANOVA indicates analysis of 
variance; COX, cyclooxygenase; and 
eNOS, endothelial nitric oxide synthase.
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relating to control of blood pressure, vascular tone, and vas-
cular hormones to extract leads for understanding how renal 
COX-2 can regulate systemic cardiovascular homeostasis. 
Using this approach, we identified a number of groups of 
genes, for example, related to ET and angiotensin signal-
ing. Angiotensin genes were altered in a way that would not 
predict cardiovascular side effects and so were not pursued 
in this study. Changes in ET-1 genes may well be impor-
tant in the effects of NSAIDs in some settings, but, in our 
model using healthy mice, the changes we found in the renal 
medulla did not ultimately affect plasma ET-1 levels or vas-
cular responses to ET-1 in the aorta ex vivo. We therefore 
focused our study around genes altered that regulate the 
synthesis and metabolism of the endogenous eNOS inhibi-
tors ADMA and l-NMMA. The kidney is a major site of 
methylarginine synthesis and clearance from the circula-
tion and changes to these pathways have the potential to 
systemically regulate vascular health. Specifically, Prmt1, 
first identified because of its association with the TIS21 
gene,36 methylates arginine residues in proteins leading to 
the release of mature ADMA and l-NMMA after proteoly-
sis, was increased by COX-2 deletion, whereas both Agxt237 
and Ddah131, enzymes that metabolize methylarginines, 
were decreased in COX-2–/– renal medulla.
To define the interaction between COX-2 and the methylar-
ginine pathways and to validate biologically our gene expres-
sion data, we measured the levels of ADMA, SDMA, and 
l-NMMA. ADMA and l-NMMA are both competitive inhibi-
tors of eNOS, whereas SDMA is biologically inactive and not 
cleared by DDAH1. COX-1–/– mice exhibited normal renal, 
plasma, and urinary levels of each methylarginine. In contrast, 
the plasma levels of ADMA and l-NMMA were increased, 
whereas l-arginine was unchanged, in samples from COX-2–/– 
mice. These findings are in line with others showing increased 
methylarginines in models where the activity of PRMT1 is 
elevated and AGXT2 is reduced.29 We found that SDMA is 
not significantly increased in COX-2–/– mouse plasma, impli-
cating an additional functional role for reduced DDAH1 in 
this model. It should be noted that nonrenal factors may act 
together with events in the kidney to regulate plasma ADMA 
in COX-2–/– mice.
After demonstrating that COX-2 deletion increases 
ADMA and l-NMMA, we next sought to establish if 
this could be recapitulated with a therapeutically rel-
evant COX-2 selective drug in wild-type mice. We chose 
parecoxib, which is the prodrug of valdecoxib and a licensed 
therapy for acute pain. It is highly COX-2 selective,1 and, 
because it is water soluble, it can be easily administered 
to mice in drinking water. Similar to our findings in COX-
2–/– mice, pharmacological COX-2 inhibition by parecoxib 
produced an increase in circulating levels of ADMA and 
l-NMMA. This further supports our findings, confirming 
that increased levels of endogenous NOS inhibitors is not 
a developmental consequence of COX-2 deletion; rather, it 
is an acute biochemical consequence of the loss of COX-2 
enzyme activity.
We have shown previously that the global heterozy-
gous deletion of the Ddah1 gene results in increased lev-
els of plasma ADMA and l-NMMA and increased blood 
pressure31 similar in magnitude to that seen in the current 
study. Further, we have demonstrated that plasma increases 
of ADMA and l-NMMA in Ddah1-deficient mice, in the 
concentration range shown here in COX-2–/– mice, were 
associated with vascular dysfunction manifesting as 
reduced acetylcholine-induced vasodilator responses in 
endothelium intact segments of aorta.31 In the aorta, ace-
tylcholine-induced vasodilation is mediated predominately 
by NO derived from eNOS, with no role for local prosta-
cyclin release. Thus, in this work, the loss of acetylcho-
line-induced vasodilation was attributed to the inhibition 
of eNOS as a direct consequence of increased ADMA and 
l-NMMA.31 In the current study, we have taken a similar 
approach and found that aorta from COX-2–/– mice had a 
reduced eNOS-dependent response to acetylcholine, but a 
normal response to the endothelial-independent NO donor 
SNP. This observation is consistent with recent work from 
others showing reduced eNOS activity in the aorta of COX-
2–/– mice,26 although, in that study, a role for natural eNOS 
inhibitors was not addressed. ADMA and l-NMMA are 
competitive inhibitors of eNOS, and, as such, their effects 
are reversed when the natural substrate, l-arginine, is 
increased in the system.38 To establish the specific role of 
ADMA and l-NMMA in the loss of eNOS function in the 
aorta, in our study, we assessed the ability of l-arginine to 
rescue the vascular dysfunction. In wild-type mouse aorta, 
l-arginine did not amplify acetylcholine-induced vasodila-
tion, consistent with l-arginine availability not being rate 
limiting in healthy blood vessels.39 In contrast, l-arginine 
reversed the impairment in endothelial function present in 
aorta from COX-2–/– mice; returning acetylcholine-depen-
dent vasodilation to wild-type levels, without affecting 
smooth muscle sensing of NO. It must be remembered that 
this effect cannot be explained by any loss of COX-2 activ-
ity locally within the vessel, because, in this tissue, COX-1, 
and not COX-2, is expressed.11,14 Rather, this is explained 
by changes in kidney function, leading to increased circu-
lating ADMA and l-NMMA, which then act in a endocrine 
manner on the endothelium in the systemic circulation. Our 
findings that the reduced eNOS activity seen in vessels from 
COX-2–/– mice could be prevented by exogenous l-arginine 
clearly implicate a role for ADMA and l-NMMA and are 
in line with others showing that ADMA and l-NMMA spe-
cifically and actively accumulate in endothelial cells and 
that this results in decreased eNOS activity ex vivo, which 
is reversible by l-arginine.40
Finally, to establish if the phenomenon demonstrated in 
mice, ie, that loss/inhibition of COX-2 results in increased 
circulating levels of ADMA also occurs in humans, we per-
formed a clinical study in which healthy male volunteers 
were treated with standard doses of the selective COX-2 
inhibitor celecoxib or naproxen, a dual COX-1/COX-2 
inhibitor.1 At therapeutic doses, both of these drugs inhibit 
COX-2 by ≈ 80%.1 Creatinine levels were increased to a 
similar level by celecoxib and naproxen treatment high-
lighting the effect of COX-2 inhibition on renal function. In 
direct corroboration of our findings in mice, both celecoxib 
and naproxen increased ADMA levels. These observations 
suggest that, in humans, after even short-term inhibition of 
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COX-2, renal dysfunction, including the reduction in filtra-
tion drive, increases the levels of ADMA. It is important to 
note, however, that ADMA, l-NMMA, and SDMA are simi-
larly cleared by the kidney. Thus, the finding that ADMA is 
increased without a concomitant increase in other methylar-
ginines suggests that some additional specific pathways may 
be altered by COX-2 inhibition. We recognize that the rela-
tive change in ADMA levels in our human study was much 
lower than seen in either COX-2–/– mice or in wild-type mice 
treated with a COX-2 inhibitor. We do not suggest that, in 
this small sample size with healthy volunteers, the increase 
would be sufficient to adversely affect cardiovascular func-
tion, simply that, it provides a proof-of-concept study and 
that, in a much larger cohort, such as the Framingham 
study41 and in patients with inflammation or cardiovascu-
lar disease, this small but significant increase could account 
for the equally small but significant increase in cardio-
vascular events seen in patients taking anti-inflammatory 
drugs, including COX-2 inhibitors. Indeed, as reported in 
the Framingham study41 in large populations, even rela-
tively small changes in ADMA levels are associated with 
significant increases in the risk of cardiovascular events, 
and the plasma levels of ADMA and l-NMMA, which oth-
ers have shown specifically can accumulate in endothelial 
cells,40 are highly correlated with cardiovascular disease in a 
range of human clinical studies.42–46 This is relevant because 
COX-2 selective drugs, including celecoxib and rofecoxib, 
increase the risk of cardiovascular events even in healthy 
individuals – that is to say, in those people without overt 
evidence of cardiovascular disease, requiring medication, 
or recent previous events, because these individuals were 
excluded from trials. Furthermore, although the efficacy tri-
als for COX-2 inhibitors were performed in patients with 
arthritis,47 who are commonly in a category of increased 
risk of cardiovascular disease owing to general inflamma-
tion and age, the Adenomatous Polyp Prevention on Vioxx 
(APPROVE)48 (rofecoxib) and Adenoma Prevention With 
Celecoxib (APC)49 (celecoxib) trials were conducted on vol-
unteers without arthritis. In both the APPROVE and APC 
trials, increased cardiovascular events were noted, which in 
the case of rofecoxib lead to the withdrawal of the drug.
The differences seen in ADMA in COX-2–/– mice and 
human volunteers taking NSAIDs for 1 week are probably 
explained by the duration and extent of loss of COX-2 activity. 
The relatively small increase in ADMA seen in humans versus 
mice administered inhibitors is less obviously explained, but 
it could be due to species differences and the fact that humans 
are outbred, and so responses are likely to be more variable. In 
addition, mice treated with parecoxib were chronically instru-
mented, which may also influence responses.
Methylarginines inhibit eNOS, reducing NO released 
across the entire vascular tree. NO performs functions similar 
to prostacyclin in vessels and platelets. Moreover, NO and 
prostacyclin synergize strongly to inhibit platelet activation.27 
Our data provide the first explanation for how the inhibition 
of COX-2 in the kidney can lead to reduced vascular function 
and firmly establish a COX-2/eNOS axis involving ADMA. 
Our results also show that ADMA and other methylarginines 
are potential biomarkers for the cardiovascular risk in patients 
taking traditional NSAIDs, and COX-2 selective inhibitors, 
as well. In addition, if endogenous inhibitors of NOS are 
mechanistically involved in the cardiovascular toxicity asso-
ciated with COX-2 inhibitor use in humans, then there is the 
very clear potential for l-arginine to be used as a preventa-
tive treatment in at-risk patients.50 Moreover, the potential for 
genetic mutations in genes such as PRMT1, DDAH1, and 
AGXT2 to be associated with increased risk of cardiovascular 
side effects in patients taking NSAIDs should be considered.
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CLINICAL PERSPECTIVE
Nonsteroidal anti-inflammatory drugs are the most common over-the-counter medications worldwide and the mainstay ther-
apy for those with chronic inflammatory conditions such as arthritis. Cyclooxygenase (COX)-2 is the therapeutic target of 
nonsteroidal anti-inflammatory drugs, but these drugs also inhibit the constitutive form COX-1, potentially causing serious 
gastrointestinal side effects. COX-2 selective drugs, such as celecoxib and rofecoxib, were introduced to reduce gastrointes-
tinal side effects. However, it is now clear that COX-2 selective anti-inflammatory drugs and older-style nonsteroidal anti-
inflammatory drugs like ibuprofen and diclofenac increase the risk of cardiovascular events. These side effects are relatively 
rare, but concern over them has meant that there has been a return to prescribing older style drugs, which generally carry a 
similar risk of heart attacks and strokes but with the added disadvantage of increased gastrointestinal side effects. Currently 
there is no accepted unifying mechanism to explain how COX-2 inhibitors cause cardiovascular side effects, and, conse-
quently, there are no biomarkers or rescue strategies to identify or treat those few individuals who might be at risk. Our study 
shows methylarginines, which block cardioprotective endothelial nitric oxide synthase in vessels, are elevated when COX-2 
is inhibited. Methylarginines are elevated in a range of cardiovascular diseases and as such are considered risk factors. Our 
work suggests methylarginines may also be biomarkers of the risk associated with COX-2 inhibition. If these findings are 
validated in a larger patient group, a simple test for methylarginines could be used to identify those individuals most at risk 
for cardiovascular events while taking COX-2 inhibitors.
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-11 -10 -9 -8 -7
0
20
40
60
80
100
120
140
[ET-1]   (log M)
Fo
rc
e
(%
 o
f K
PS
S 
re
sp
on
se
) COX-2+/+
COX-2-/-
p=0.65
Wild-type COX-1-/- COX-2-/-
0
2
4
6
Pl
as
m
a 
[E
T-
1]
   
(pg
/m
l)
p=0.99
p=0.38
Supplementary Fig. 1: Effect of COX-1 and COX-2 gene deletion on (a) circulating endothelin-1 (ET-1) 
and (b) contractile effect of  ET-1 on aorta. Aorta were incubated in Krebs’ buffer containing 100 µM L-
NGmonomethyl-L-arginine to inhibit eNOS activity. Data is the mean ± S.E.M for (a) n=8-9 mice and (b) n=4 
vessels from 2 mice. Data was analysed using (a) Kruskil-Wallis with Dunn’s post-hoc test and (b) by 
Quades two-way ANOVA.
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Supplementary Fig 2: Effect of COX-2 gene deletion on Ddah2 expression in the renal medulla. The data 
is the mean mean ± S.E.M for n=7. Data was analysed using a Mann-Whitney U-test. 
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Supplementary Fig. 3: Effect of  COX-2 gene deletion on the expression of (a) Arg2 in the renal medulla, 
(b) Arg1 in the aorta and plasma levels of (c) L-arginine, (d) ratio of  ADMA: L-arginine and (e) L-NMMA:L-
arginine in the plasma. The data is the mean ± S.E.M for (a) and (b) n=7-8, (c-e) n=4. Data was analysed 
Mann-Whitney U-test. 
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Supplementary Fig. 4: Effect of  parecoxib (100 mg/kg/day) compared to vehicle (water) on plasma levels 
of (a) L-arginine and (b) ADMA:L-arginine and (c) L-NMMA:L-arginine ratios in plasma of  wild type mice. 
The data is the mean ± S.E.M n=3-7. Data was anlaysed using a Mann-Whitney U-test.
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Supplementary Fig. 5: Effect of COX-2 gene deletion on the contractile responses of  U46619 in aorta. 
The data the mean ± S.E.M for n=6-10. Data was analysed using a Quades two-way ANOVA. 
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Supplementary Fig. 6: Effect of COX-2 gene deletion on aortic expression of (a) Nos3, (b) Ddah1, (c) 
Ddah2 and (d) Agxt2. The data is the mean ± S.E.M for n=5-7 mice. Data was analysed using a Mann-
Whitney U-test
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Supplementary Fig. 7: Effect of  IP gene deletion on the expression of  (a) Prmt1, (b) Agxt2, (c) Ddah1, (d) 
Ddah2 and (e) Arg2 in the renal medulla. The data is the mean ± S.E.M n=8. Data was analysed using a 
Mann-Whitney U-test.
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Supplementary Fig. 8: (a) Effect of IP gene deletion on plasma levels of ADMA. (b) Comparison of the 
effect of  IP gene deletion versus COX-2 gene deletion on relative (fold) change in ADMA. (c) Effect of  IP 
gene deletion on plasma levels of (c) L-arginine, (d) L-NMMA and (e) creatinine. The data is the mean ± 
S.E.M for n=8. Data was analysed using Mann-Whitney U-test
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Gene$Symbol$ Fold-Change$
Igfbp2' 3.2'
'Upk2' 2.8'
'Psca' 2.5'
'Nrip3' 2.5'
'Neurl' 2.4'
'Rgs4' 2.4'
'Egr1' 2.4'
'Lypd2' 2.4'
'Npy' 2.3'
'Lyz' 2.2'
'Spnb1' 2.2'
'Cacna2d1' 2.1'
'Nbl1' 2.1'
'Loc100047934' 2.1'
'Aoc3' 2.1'
'Fbn1' 2.1'
'Lynx1' 2.1'
'Ndn' 2.1'
'Aatk' 2.1'
'Purb' 2.0'
'Zeb2' 2.0'
'Upk1b' 2.0'
'Lcn2' 2.0'
'Sprr1a' 2.0'
'Klf5' 2.0'
'Satb1' 2.0'
'Ankrd1' 1.9'
'Bc025575' 1.9'
'Cldn5' 1.9'
'Lyzs' 1.9'
'Chst1' 1.9'
'Flrt3' 1.9'
'Loc100047200' 1.9'
'Krt18' 1.9'
'Fxyd6' 1.9'
'Rab15' 1.9'
'Grit' 1.9'
'Tmem119' 1.9'
'Col16a1' 1.9'
'Krt14' 1.9'
'Nav1' 1.9'
'Loc100048721' 1.9'
'Mmp14' 1.9'
'Scarf2' 1.9'
'9130213b05rik' 1.9'
'Ccdc80' 1.9'
'Ddit4' 1.8'
'
Gene$Symbol$ Fold-Change$
Nupr1' 1.8'
'Arhgef4' 1.8'
'Stab1' 1.8'
'Ccdc3' 1.8'
'Lgals3' 1.8'
'Gpr123' 1.8'
'Jun' 1.8'
'Col6a1' 1.8'
'Spon1' 1.8'
'Slc24a3' 1.8'
'Ophn1' 1.8'
'Gprc5a' 1.8'
'Elf3' 1.8'
'F13a1' 1.8'
'Serpinf1' 1.8'
'Asah3l' 1.8'
'Cntn1' 1.8'
'Tmem118' 1.8'
'Megf9' 1.8'
'Ptprs' 1.8'
'Scara3' 1.8'
'Serpina3n' 1.8'
'D0h4s114' 1.8'
'Cyp1b1' 1.8'
'Gja1' 1.8'
'Rhoj' 1.8'
'Vwf' 1.8'
'Loc100046044' 1.8'
'Loc100043671' 1.8'
'Wnt7b' 1.8'
'Slc44a2' 1.8'
'P2ry6' 1.8'
'Bcl9l' 1.8'
'Klf6' 1.8'
'Fscn1' 1.8'
'Cldn4' 1.8'
'E430002d04rik' 1.8'
'Dusp7' 1.7'
'Upk3a' 1.7'
'Cygb' 1.7'
'Il18r1' 1.7'
'Hist1h2an' 1.7'
'Gnaz' 1.7'
'Rgs5' 1.7'
'Pip4k2a' 1.7'
'Ppp1r9b' 1.7'
'Zfp52' 1.7'
'
Gene$Symbol$ Fold-Change$
Spon2' 1.7'
'Spnb3' 1.7'
'Sppl3' 1.7'
'Sepw1' 1.7'
'Pea15' 1.7'
'Kdelr3' 1.7'
'Susd4' 1.7'
'Ctsk' 1.7'
'Ptprb' 1.7'
'Rasl11b' 1.7'
'Ssbp4' 1.7'
'Samd14' 1.7'
'Abi3' 1.7'
'Fst' 1.7'
'Tnrc6c' 1.7'
'Itgb4' 1.7'
'Cfp' 1.7'
'D12ertd553e' 1.7'
'S100a13' 1.7'
'Txnip' 1.7'
'Mmp17' 1.7'
'Anxa2' 1.7'
'Bok' 1.7'
'Serinc2' 1.7'
'Aqp2' 1.7'
'Loc100045019' 1.7'
'Cdkn1c' 1.7'
'Stat3' 1.7'
'Axin2' 1.7'
'Pof1b' 1.7'
'Laptm5' 1.7'
'F2r' 1.7'
'Endod1' 1.7'
'Atf5' 1.7'
'C030011o14rik' 1.7'
'D16ertd472e' 1.7'
'Hist1h2af' 1.7'
'Stxbp1' 1.7'
'Ckb' 1.7'
'2310022b05rik' 1.7'
'Tmem110' 1.7'
'Ap3m2' 1.7'
'Gjb6' 1.7'
'Ankrd47' 1.7'
'Col1a2' 1.7'
'Des' 1.7'
'H2^aa' 1.7'
'
Gene$Symbol$ Fold-Change$
Gp38' 1.7'
'Ppp1r3c' 1.7'
'Emid2' 1.7'
'Crip2' 1.6'
'Notch1' 1.6'
'Ier3' 1.6'
'Fcho1' 1.6'
'Slco4a1' 1.6'
'Lrrc26' 1.6'
'Nnmt' 1.6'
'Tiam1' 1.6'
'Actb' 1.6'
'Prkcbp1' 1.6'
'Dkk3' 1.6'
'Myo9b' 1.6'
'Dusp26' 1.6'
'Slc2a6' 1.6'
'Pitpnm2' 1.6'
'2310010m24rik' 1.6'
'Adamts2' 1.6'
'Pitx2' 1.6'
'Pfkl' 1.6'
'Bace1' 1.6'
'Csnk1e' 1.6'
'Ccnd2' 1.6'
'Chrnb1' 1.6'
'Gstm2' 1.6'
'Efemp2' 1.6'
'Dag1' 1.6'
'Cav1' 1.6'
'Myd116' 1.6'
'Pdgfra' 1.6'
'Scnn1b' 1.6'
'Slc38a2' 1.6'
'Rbms3' 1.6'
'Zfp46' 1.6'
'Pdlim7' 1.6'
'Cxcl4' 1.6'
'Kctd10' 1.6'
'Wfdc2' 1.6'
'St6gal1' 1.6'
'Cbr2' 1.6'
'Bat2' 1.6'
'Timp2' 1.6'
'Sort1' 1.6'
'Ccnd1' 1.6'
'Smpdl3b' 1.6'
'
Gene$Symbol$ Fold-Change$
Fxyd4' 1.6'
'D6wsu176e' 1.6'
'Slc1a3' 1.6'
'Kpnb1' 1.6'
'Ahi1' 1.6'
'Edg2' 1.6'
'4930572j05rik' 1.6'
'Cugbp2' 1.6'
'Loc100045343' 1.6'
'Tcof1' 1.6'
'Loc676420' 1.6'
'Phc2' 1.6'
'Ccdc85b' 1.6'
'Adora1' 1.6'
'Grasp' 1.6'
'Pdlim1' 1.6'
'Gja5' 1.6'
'Sh3pxd2b' 1.6'
'Rcan2' 1.6'
'Sepn1' 1.6'
'Prelp' 1.6'
'Dusp3' 1.6'
'Capn13' 1.6'
'Mmp2' 1.6'
'Irf2bp1' 1.6'
'Sema3f' 1.6'
'Hcn2' 1.6'
'Rgs10' 1.6'
'9130404d14rik' 1.6'
'Csrp1' 1.6'
'Pik3r1' 1.6'
'Pls3' 1.6'
'Mbc2' 1.6'
'Dab2ip' 1.6'
'Meis1' 1.6'
'Axl' 1.6'
'Edn1' 1.6'
'Mef2c' 1.6'
'Pold1' 1.6'
'Ehd4' 1.6'
'Tmem23' 1.6'
'Mmrn2' 1.6'
'Bc063749' 1.6'
'Mcl1' 1.6'
'Bc057552' 1.6'
'Large' 1.6'
'Rassf5' 1.6'
'
Gene$Symbol$ Fold-Change$
Myst4' 1.6'
'Gata2' 1.6'
'Scx' 1.6'
'Sidt1' 1.6'
'A230050p20rik' 1.6'
'Npnt' 1.6'
'Traf7' 1.6'
'Spire2' 1.6'
'Esam1' 1.6'
'Magee1' 1.6'
'Pkm2' 1.6'
'Xlr4a' 1.6'
'Loc100042777' 1.6'
'Ppap2b' 1.6'
'Tspan17' 1.6'
'Itga3' 1.6'
'Serf2' 1.6'
'Csf1' 1.6'
'Sh3bgrl3' 1.6'
'Pip4k2b' 1.6'
'Psmb10' 1.6'
'Hn1' 1.6'
'Bc021381' 1.5'
'Col18a1' 1.5'
'Btg1' 1.5'
'Notch4' 1.5'
'Rapgefl1' 1.5'
'Fmnl3' 1.5'
'Cldn23' 1.5'
'Upk1a' 1.5'
'Dusp8' 1.5'
'Phactr1' 1.5'
'Mospd3' 1.5'
'Foxj2' 1.5'
'Smarcd2' 1.5'
'Arrdc2' 1.5'
'Rem1' 1.5'
'Slc9a1' 1.5'
'Pdxp' 1.5'
'Pacs1' 1.5'
'Mmd' 1.5'
'Olfml3' 1.5'
'Akap8l' 1.5'
'Hoxd4' 1.5'
'Pygo2' 1.5'
'Mfap2' 1.5'
'8430408g22rik' 1.5'
'
Gene$Symbol$ Fold-Change$
Vamp2' 1.5'
'Cox4i2' 1.5'
'Ahdc1' 1.5'
'Ptk7' 1.5'
'Arid2' 1.5'
'Ptplad2' 1.5'
'Tubb2b' 1.5'
'Fpr2' 1.5'
'Socs3' 1.5'
'Hmha1' 1.5'
'Zfhx3' 1.5'
'Cdc42ep5' 1.5'
'Tcf4' 1.5'
'Atox1' 1.5'
'Vat1' 1.5'
'Cpne2' 1.5'
'Mmp23' 1.5'
'Dpt' 1.5'
'Tkt' 1.5'
'Fxyd5' 1.5'
'Scamp5' 1.5'
'Atp6v0a1' 1.5'
'Ednrb' 1.5'
'S100a6' 1.5'
'Hexa' 1.5'
'2300002d11rik' 1.5'
'Zfp259' 1.5'
'Smtn' 1.5'
'Aip' 1.5'
'Stx12' 1.5'
'Spink8' 1.5'
'Loc100047619' 1.5'
'Tubb6' 1.5'
'Bmpr1b' 1.5'
'Nfatc4' 1.5'
'Loc641240' 1.5'
'Brd2' 1.5'
'Slc4a2' 1.5'
'Capn5' 1.5'
'Rab31' 1.5'
'Rgma' 1.5'
'Atpbd1b' 1.5'
'Gfod2' 1.5'
'Efna5' 1.5'
'Krt7' 1.5'
'Flywch2' 1.5'
'Cdh1' 1.5'
'
Gene$Symbol$ Fold-Change$
Slco2a1' ^1.5'
'Gpr177' ^1.5'
'Syap1' ^1.5'
'Dock1' ^1.5'
'Mto1' ^1.5'
'Tmem174' ^1.5'
'Commd1' ^1.5'
'1110031b06rik' ^1.5'
'Ppp1ca' ^1.5'
'Ppapdc1' ^1.5'
'Tpk1' ^1.5'
'Acox2' ^1.5'
'Spg21' ^1.5'
'Cul3' ^1.5'
'Pycrl' ^1.5'
'Atpif1' ^1.5'
'Nrbf2' ^1.5'
'Pdss1' ^1.5'
'Mcat' ^1.5'
'2410022l05rik' ^1.5'
'Fcgr2b' ^1.5'
'Creld2' ^1.5'
'Eif4g2' ^1.5'
'Hax1' ^1.5'
'Rps27a' ^1.5'
'D10bwg1364e' ^1.5'
'Acad10' ^1.5'
'1500032l24rik' ^1.5'
'Sdf2' ^1.5'
'Loc100048331' ^1.5'
'Ctsf' ^1.5'
'Xdh' ^1.5'
'2810439f02rik' ^1.5'
'Letm1' ^1.5'
'Slc5a9' ^1.5'
'Ak2' ^1.5'
'Zc3h14' ^1.5'
'E030010a14rik' ^1.5'
'Caml' ^1.5'
'Hpn' ^1.5'
'Cd55' ^1.5'
'Zfp207' ^1.5'
'Ccnc' ^1.5'
'Sod1' ^1.5'
'Errfi1' ^1.5'
'Aqp7' ^1.5'
'Akr1c14' ^1.5'
'
Gene$Symbol$ Fold-Change$
Fads2' ^1.5'
'Aadacl1' ^1.5'
'Strap' ^1.5'
'Gm2a' ^1.5'
'Rheb' ^1.5'
'1810049h13rik' ^1.5'
'Loc100047261' ^1.5'
'Tnfrsf21' ^1.5'
'Surf1' ^1.5'
'Ppm1g' ^1.5'
'Eg434858' ^1.5'
'Glb1l2' ^1.5'
'Hspe1' ^1.5'
'4930403o06rik' ^1.5'
'Mgst1' ^1.5'
'Dnajb9' ^1.5'
'Snx6' ^1.5'
'Ttc8' ^1.5'
'Pdcl' ^1.5'
'Med21' ^1.5'
'Rpl31' ^1.5'
'Slc6a20b' ^1.5'
'Fgf9' ^1.5'
'Adfp' ^1.5'
'Slc41a2' ^1.5'
'Fga' ^1.5'
'Slc9a8' ^1.5'
'Gng10' ^1.5'
'5730469m10rik' ^1.5'
'Loc677528' ^1.5'
'Tmem159' ^1.5'
'Dcun1d4' ^1.5'
'Mboat5' ^1.5'
'Dnajb12' ^1.5'
'Rab38' ^1.5'
'Rpl36al' ^1.5'
'Cyp27a1' ^1.5'
'Iyd' ^1.5'
'Tm2d3' ^1.5'
'Atp5s' ^1.5'
'Sat2' ^1.5'
'Uqcrc2' ^1.6'
'Mrpl30' ^1.6'
'Nsdhl' ^1.6'
'Nqo1' ^1.6'
'Med10' ^1.6'
'Epdr1' ^1.6'
'
Gene$Symbol$ Fold-Change$
Ubr1' ^1.6'
'Chchd4' ^1.6'
'Ndufa9' ^1.6'
'Ogfrl1' ^1.6'
'Eno1' ^1.6'
'Rnaset2b' ^1.6'
'Arf5' ^1.6'
'Suclg1' ^1.6'
'Wdr55' ^1.6'
'Loc667370' ^1.6'
'Sri' ^1.6'
'Tceal8' ^1.6'
'4933434e20rik' ^1.6'
'Fundc1' ^1.6'
'Cldn1' ^1.6'
'Pfkp' ^1.6'
'Net1' ^1.6'
'L7rn6' ^1.6'
'Decr2' ^1.6'
'Arpc1a' ^1.6'
'Tmem85' ^1.6'
'Pdzd11' ^1.6'
'Ostf1' ^1.6'
'Fmo4' ^1.6'
'Pcmt1' ^1.6'
'Hist1h4h' ^1.6'
'Dynll2' ^1.6'
'Dpy30' ^1.6'
'5033414d02rik' ^1.6'
'Dab2' ^1.6'
'Als2cr2' ^1.6'
'Rps12' ^1.6'
'Steap2' ^1.6'
'Slc25a33' ^1.6'
'Slc35a1' ^1.6'
'Tmem131' ^1.6'
'Hpd' ^1.6'
'Papss2' ^1.6'
'Tomm7' ^1.6'
'Yif1a' ^1.6'
'Cyb5r4' ^1.6'
'Mrps31' ^1.6'
'Actn4' ^1.6'
'Rab17' ^1.6'
'Sypl' ^1.6'
'Atp6v0e' ^1.6'
'Mrpl40' ^1.6'
'
Gene$Symbol$ Fold-Change$
Exoc4' ^1.6'
'Cpn1' ^1.6'
'Tmem5' ^1.6'
'Susd3' ^1.6'
'Msrb2' ^1.6'
'Psmd12' ^1.6'
'Insig2' ^1.6'
'Gstt2' ^1.6'
'Dnajc15' ^1.6'
'Nsbp1' ^1.6'
'Cobll1' ^1.6'
'Prosc' ^1.6'
'Rala' ^1.6'
'Bxdc2' ^1.6'
'Eif2b1' ^1.6'
'P2rx4' ^1.6'
'Htatip2' ^1.6'
'Maea' ^1.6'
'Kctd12' ^1.6'
'Iars2' ^1.6'
'Sypl2' ^1.6'
'Vps29' ^1.6'
'Snrpd1' ^1.6'
'Bc048355' ^1.6'
'Napsa' ^1.6'
'Htra1' ^1.6'
'Rab1b' ^1.6'
'2810008m24rik' ^1.6'
'Atp5d' ^1.6'
'Nsmaf' ^1.6'
'Hagh' ^1.6'
'Cyp4f14' ^1.6'
'Pitpnc1' ^1.6'
'Efr3a' ^1.6'
'1700034h14rik' ^1.6'
'Tbca' ^1.6'
'Gtpbp4' ^1.6'
'Ppp2cb' ^1.6'
'Acn9' ^1.6'
'4931417g12rik' ^1.6'
'Gjb2' ^1.6'
'Fbxo9' ^1.6'
'Slc34a3' ^1.6'
'Bc026682' ^1.6'
'Hmox2' ^1.6'
'A030007l17rik' ^1.6'
'Loc100047012' ^1.6'
'
Gene$Symbol$ Fold-Change$
Dusp28' ^1.6'
'Loc668492' ^1.6'
'1110038d17rik' ^1.6'
'Metap1' ^1.6'
'Mettl9' ^1.6'
'Tmem9b' ^1.6'
'Ubl5' ^1.6'
'Stx18' ^1.6'
'Rcan1' ^1.6'
'Arl3' ^1.6'
'Capns1' ^1.6'
'Mrps16' ^1.6'
'Akr1c12' ^1.6'
'Tmem77' ^1.6'
'Ranbp9' ^1.6'
'Zfyve20' ^1.6'
'Ddx1' ^1.6'
'Agps' ^1.6'
'Calm2' ^1.6'
'Anpep' ^1.6'
'Serpina1f' ^1.6'
'Gchfr' ^1.6'
'Ccdc47' ^1.6'
'Ostm1' ^1.6'
'2010316f05rik' ^1.7'
'Thoc4' ^1.7'
'Ndufa4' ^1.7'
'Nxt2' ^1.7'
'Nbr1' ^1.7'
'1300018j18rik' ^1.7'
'Top1' ^1.7'
'Agpat2' ^1.7'
'Rnf11' ^1.7'
'Echs1' ^1.7'
'Tspo' ^1.7'
'Entpd5' ^1.7'
'Arl6ip5' ^1.7'
'Afmid' ^1.7'
'Loc100046457' ^1.7'
'Rabggtb' ^1.7'
'Atp5j' ^1.7'
'Nat2' ^1.7'
'Hsd17b2' ^1.7'
'Hdhd2' ^1.7'
'Pcbd1' ^1.7'
'2510010f15rik' ^1.7'
'Fkbp2' ^1.7'
'
Gene$Symbol$ Fold-Change$
Sec61b' ^1.7'
'Tmem106a' ^1.7'
'Car3' ^1.7'
'1810022c23rik' ^1.7'
'Galnt1' ^1.7'
'Synj2bp' ^1.7'
'Bc040758' ^1.7'
'Lrrc8' ^1.7'
'Col4a5' ^1.7'
'Rpl27' ^1.7'
'Dtymk' ^1.7'
'1110019n10rik' ^1.7'
'Ndufc1' ^1.7'
'Mlstd2' ^1.7'
'Psen1' ^1.7'
'Ly6c1' ^1.7'
'2410129h14rik' ^1.7'
'2310045a20rik' ^1.7'
'Hmgn2' ^1.7'
'Fbxo3' ^1.7'
'Mrpl22' ^1.7'
'Zfp313' ^1.7'
'Cnih' ^1.7'
'Dcxr' ^1.7'
'Klhl9' ^1.7'
'Acss2' ^1.7'
'Leprel1' ^1.7'
'4631427c17rik' ^1.7'
'Pcx' ^1.7'
'Fads3' ^1.7'
'Mrpl9' ^1.7'
'Ndrl' ^1.7'
'Hpgd' ^1.7'
'Dnajc6' ^1.7'
'Gstp1' ^1.7'
'Ubb' ^1.7'
'Btf3' ^1.7'
'Jak2' ^1.7'
'Ube2e3' ^1.7'
'Pvalb' ^1.7'
'Tfg' ^1.7'
'Pcca' ^1.7'
'Mpv17l' ^1.7'
'Uchl3' ^1.7'
'Acsm5' ^1.7'
'Tnfaip8' ^1.7'
'Serpina1d' ^1.7'
'
Gene$Symbol$ Fold-Change$
Qdpr' ^1.7'
'Lpar3' ^1.7'
'Car12' ^1.7'
'Ncoa4' ^1.7'
'Gnas' ^1.7'
'Trappc4' ^1.7'
'Ufsp2' ^1.7'
'1500031l02rik' ^1.7'
'Cideb' ^1.7'
'Gm1821' ^1.7'
'Tmem166' ^1.7'
'Ppp1cb' ^1.7'
'Mcts1' ^1.7'
'Mpst' ^1.7'
'Clptm1' ^1.7'
'Gcdh' ^1.7'
'Tmem116' ^1.7'
'Mdh1' ^1.7'
'Klk1b5' ^1.7'
'Rbbp7' ^1.7'
'Slc22a18' ^1.7'
'Crym' ^1.7'
'Ppp2r1a' ^1.8'
'Mrpl4' ^1.8'
'Asl' ^1.8'
'Suclg2' ^1.8'
'Xylb' ^1.8'
'Nhsl1' ^1.8'
'Hnrpf' ^1.8'
'Sdhb' ^1.8'
'Loc654426' ^1.8'
'Cyba' ^1.8'
'Zfp810' ^1.8'
'Hnrph1' ^1.8'
'Tmed10' ^1.8'
'Pcdh24' ^1.8'
'G6pc' ^1.8'
'Tmem41a' ^1.8'
'Mrps22' ^1.8'
'Plscr2' ^1.8'
'Ces3' ^1.8'
'Sumo2' ^1.8'
'Gss' ^1.8'
'D10ertd322e' ^1.8'
'Pdia3' ^1.8'
'Eef1e1' ^1.8'
'Rars2' ^1.8'
'
Gene$Symbol$ Fold-Change$
0610012d14rik' ^1.8'
'Rps16' ^1.8'
'Eg632778' ^1.8'
'Tfam' ^1.8'
'Sqstm1' ^1.8'
'Proc' ^1.8'
'Bud31' ^1.8'
'Socs2' ^1.8'
'Echdc2' ^1.8'
'Eg622339' ^1.8'
'Ndufa12' ^1.8'
'Kl' ^1.8'
'Plscr1' ^1.8'
'Pgam1' ^1.8'
'Fh1' ^1.8'
'Rnf4' ^1.8'
'Loc100048480' ^1.8'
'Atp6v1g1' ^1.8'
'Ddx52' ^1.8'
'Coasy' ^1.8'
'Cox15' ^1.8'
'Jtb' ^1.8'
'Tmem9' ^1.8'
'Rab18' ^1.8'
'Usp16' ^1.8'
'Capn7' ^1.8'
'Ntan1' ^1.8'
'Rps27l' ^1.8'
'Mertk' ^1.8'
'Ube2k' ^1.8'
'Rps13' ^1.8'
'Gde1' ^1.8'
'Nfs1' ^1.8'
'Rpl9' ^1.8'
'Thnsl2' ^1.8'
'Ufc1' ^1.8'
'2310005n03rik' ^1.8'
'Ap2a2' ^1.8'
'Bc051227' ^1.8'
'Ccdc91' ^1.8'
'2610204l23rik' ^1.8'
'Nap1l1' ^1.8'
'Acad8' ^1.8'
'Bc038156' ^1.9'
'Agt' ^1.9'
'Efhd1' ^1.9'
'Paqr9' ^1.9'
'
Gene$Symbol$ Fold-Change$
Acsl1' ^1.9'
'Cndp1' ^1.9'
'Il13ra1' ^1.9'
'Sqle' ^1.9'
'Sod3' ^1.9'
'Wwp1' ^1.9'
'Scoc' ^1.9'
'Sult1d1' ^1.9'
'Adss' ^1.9'
'Slc39a11' ^1.9'
'Cmbl' ^1.9'
'Acaa2' ^1.9'
'Hspd1' ^1.9'
'Mrpl18' ^1.9'
'Tmco3' ^1.9'
'Atp5l' ^1.9'
'Nudt19' ^1.9'
'Galm' ^1.9'
'Eif5a' ^1.9'
'Gna11' ^1.9'
'Slc13a3' ^1.9'
'Tst' ^1.9'
'Gsto1' ^1.9'
'Scl0003251.1_2
1' ^1.9'
'Znrf2' ^1.9'
'Grpel1' ^1.9'
'Slc35a3' ^1.9'
'Il1rl1l' ^1.9'
'Pex7' ^1.9'
'Ppt1' ^1.9'
'Mrpl3' ^1.9'
'As3mt' ^1.9'
'Pdia4' ^1.9'
'Nit2' ^1.9'
'Nudt4' ^1.9'
'Morf4l1' ^1.9'
'Eif3s8' ^1.9'
'9630015d15rik' ^1.9'
'Ceacam2' ^1.9'
'Nox4' ^1.9'
'Sap30' ^1.9'
'Cml1' ^1.9'
'Atp5o' ^1.9'
'Adhfe1' ^1.9'
'Commd3' ^1.9'
'Psmb7' ^1.9'
'
Gene$Symbol$ Fold-Change$
Dpep1' ^1.9'
'Slc22a2' ^1.9'
'Hist1h2bm' ^1.9'
'Cox7a2l' ^1.9'
'Loc100043257' ^1.9'
'Myo5a' ^1.9'
'Msn' ^1.9'
'Rps4x' ^1.9'
'Car4' ^1.9'
'Nus1' ^1.9'
'Pepd' ^1.9'
'Arl5a' ^1.9'
'Gpr137b' ^1.9'
'Slc6a13' ^1.9'
'Pdzd3' ^2.0'
'Ndufb6' ^2.0'
'Hnrnpa2b1' ^2.0'
'Timm8b' ^2.0'
'Ccbl2' ^2.0'
'Tmem126a' ^2.0'
'Car14' ^2.0'
'Pbld' ^2.0'
'2810410p22rik' ^2.0'
'Eif3eip' ^2.0'
'Zmynd10' ^2.0'
'Rdh14' ^2.0'
'Bola3' ^2.0'
'Mapk14' ^2.0'
'Aqp11' ^2.0'
'Lonp2' ^2.0'
'A530050d06rik' ^2.0'
'Gfm1' ^2.0'
'Ndufa6' ^2.0'
'0610010d20rik' ^2.0'
'Rpl24' ^2.0'
'4833421e05rik' ^2.0'
'Arsb' ^2.0'
'Adh5' ^2.0'
'Dhrs1' ^2.0'
'Capn2' ^2.0'
'Acadm' ^2.0'
'Slc13a2' ^2.0'
'Snx7' ^2.0'
'Loc100047353' ^2.0'
'Tmem139' ^2.0'
'H47' ^2.0'
'Cyc1' ^2.0'
'
Gene$Symbol$ Fold-Change$
Sumo3' ^2.0'
'Hsd17b11' ^2.0'
'Slc2a2' ^2.0'
'Akr1a4' ^2.0'
'Cbs' ^2.0'
'Loc100046650' ^2.0'
'Abcc2' ^2.0'
'Tcp1' ^2.0'
'Dio1' ^2.1'
'Slc26a4' ^2.1'
'Syngr2' ^2.1'
'Slc25a5' ^2.1'
'Tfrc' ^2.1'
'Hip2' ^2.1'
'Ctsh' ^2.1'
'Tsc22d1' ^2.1'
'Gatad1' ^2.1'
'Rab5a' ^2.1'
'Cth' ^2.1'
'Rps2' ^2.1'
'Aldh1l1' ^2.1'
'Bpnt1' ^2.1'
'Slc46a3' ^2.1'
'Zfp330' ^2.1'
'Mme' ^2.1'
'Jam4' ^2.1'
'L2hgdh' ^2.1'
'Tmem59' ^2.1'
'Frrs1' ^2.1'
'5730437n04rik' ^2.1'
'Slc7a9' ^2.1'
'1810063b05rik' ^2.1'
'Vil1' ^2.1'
'Ebp' ^2.1'
'Agxt2' ^2.1'
'Dgat2' ^2.1'
'Apom' ^2.1'
'Sar1b' ^2.1'
'Loc667609' ^2.1'
'Sult1c2' ^2.1'
'Cyp2j11' ^2.1'
'Gsta2' ^2.1'
'Kdelr2' ^2.1'
'Higd1c' ^2.1'
'Hist1h2bj' ^2.1'
'Bc026585' ^2.1'
'Cyp2d26' ^2.1'
'
Gene$Symbol$ Fold-Change$
2310008m10rik' ^2.1'
'Nola3' ^2.1'
'Dpp4' ^2.2'
'Mtap7' ^2.2'
'Ahcyl1' ^2.2'
'Nt5e' ^2.2'
'Spcs1' ^2.2'
'Etfa' ^2.2'
'Loc100045567' ^2.2'
'Sepp1' ^2.2'
'Bc055107' ^2.2'
'Bc016495' ^2.2'
'Acad9' ^2.2'
'1110008f13rik' ^2.2'
'Slc25a15' ^2.2'
'Pcbp2' ^2.2'
'Nudt12' ^2.2'
'Ubie' ^2.2'
'Ottmusg000000
05148' ^2.2'
'Slc5a2' ^2.2'
'Slc25a30' ^2.2'
'Sfrs5' ^2.2'
'Adi1' ^2.2'
'Loc677144' ^2.2'
'Ela1' ^2.2'
'B230339h12rik' ^2.2'
'Sigirr' ^2.2'
'Supt4h2' ^2.2'
'Slc12a3' ^2.2'
'Khk' ^2.2'
'2010311d03rik' ^2.2'
'Dars' ^2.3'
'Bc021608' ^2.3'
'Smpdl3a' ^2.3'
'Bc021785' ^2.3'
'H2afz' ^2.3'
'Agtr1a' ^2.3'
'Ak3l1' ^2.3'
'Pdhb' ^2.3'
'Ndfip1' ^2.3'
'Slc25a36' ^2.3'
'Ndufc2' ^2.3'
'Nola2' ^2.3'
'F13b' ^2.3'
'Rpl7a' ^2.3'
'Iah1' ^2.3'
'
Gene$Symbol$ Fold-Change$
Gnmt' ^2.3'
'D630023f18rik' ^2.3'
'Loc100045617' ^2.3'
'Ldhd' ^2.3'
'Pdk3' ^2.3'
'Tinag' ^2.3'
'Eef2' ^2.3'
'Defb29' ^2.3'
'Vdac3' ^2.4'
'Abhd3' ^2.4'
'Acot3' ^2.4'
'Loc381629' ^2.4'
'Upb1' ^2.4'
'Cryz' ^2.4'
'Loc268782' ^2.4'
'Tspan3' ^2.4'
'Bc006662' ^2.4'
'Bhmt2' ^2.4'
'Tmem33' ^2.4'
'Galnt11' ^2.4'
'Ppa2' ^2.4'
'Calr' ^2.4'
'Hist1h2bn' ^2.5'
'Hao3' ^2.5'
'Loc100044204' ^2.5'
'Calml4' ^2.5'
'H3f3a' ^2.5'
'C1qbp' ^2.5'
'Qprt' ^2.5'
'Mtch2' ^2.5'
'Arl6' ^2.5'
'Ai317395' ^2.5'
'Slc7a7' ^2.5'
'Dnajc12' ^2.5'
'2610528j11rik' ^2.5'
'Sucnr1' ^2.5'
'Cct6a' ^2.5'
'Igfbp3' ^2.5'
'Pah' ^2.5'
'Loc100048413' ^2.5'
'Frap1' ^2.5'
'Ddc' ^2.5'
'Klk1b4' ^2.5'
'Hist1h2bh' ^2.6'
'Vps35' ^2.6'
'Eps8' ^2.6'
'Loc433479' ^2.6'
'
Gene$Symbol$ Fold-Change$
Ndufs2' ^2.6'
'Pxmp2' ^2.6'
'Slc19a1' ^2.6'
'Ai747699' ^2.6'
'Gstm5' ^2.6'
'Ppcs' ^2.6'
'Folr1' ^2.6'
'Clrn3' ^2.6'
'Hist1h2bf' ^2.6'
'Bc026439' ^2.6'
'Cldn2' ^2.6'
'Lrrk2' ^2.6'
'Loc100047046' ^2.7'
'D630042f21rik' ^2.7'
'Csad' ^2.7'
'Etfdh' ^2.7'
'Mrpl53' ^2.7'
'Nme2' ^2.7'
'Chuk' ^2.7'
'Fgf1' ^2.7'
'Hint1' ^2.7'
'Dhrs4' ^2.7'
'Col4a3' ^2.8'
'Loc100047937' ^2.8'
'Mpp1' ^2.8'
'Sephs2' ^2.8'
'Coq9' ^2.8'
'Ugt3a2' ^2.8'
'Rps6' ^2.9'
'Kng2' ^2.9'
'Loc333331' ^2.9'
'Gm853' ^2.9'
'Prdx3' ^2.9'
'Fmo1' ^2.9'
'Nckap1' ^2.9'
'Ostb' ^2.9'
'Glud1' ^2.9'
'Oxct1' ^3.0'
'Pcbp1' ^3.0'
'Mep1b' ^3.1'
'Cat' ^3.1'
'Rbpms2' ^3.2'
'Slc27a2' ^3.2'
'Plekhb2' ^3.2'
'Slc6a19' ^3.2'
'Rgl1' ^3.2'
'Slc22a9' ^3.2'
'
Gene$Symbol$ Fold-Change$
Ivns1abp' ^3.2'
'Slc47a1' ^3.3'
'5033411d12rik' ^3.3'
'Ugt3a1' ^3.3'
'2500002l14rik' ^3.3'
'Rps7' ^3.4'
'Klk1b27' ^3.4'
'Lgmn' ^3.5'
'Slc17a3' ^3.6'
'Cyp4a31' ^3.6'
'Gpx1' ^3.6'
'Rnaset2' ^3.7'
'Tcn2' ^3.8'
'Cml3' ^3.9'
'Ehhadh' ^3.9'
'Slc16a4' ^4.0'
'Idh1' ^4.0'
'Fbp1' ^4.2'
'Scp2' ^4.2'
'Spp2' ^4.3'
'Slc22a13' ^4.3'
'Hrsp12' ^4.5'
'Atp5f1' ^5.0'
'Miox' ^5.0'
'Eg433923' ^5.1'
'Chpt1' ^5.3'
'Loc100046918' ^5.4'
'Tmem27' ^5.6'
'Cyp51' ^5.9'
'Cyp4b1' ^6.4'
'Ugt1a10' ^6.5'
'Hspa8' ^7.6'
'Dnase1' ^8.7'
'!
Supplementary Table  2: Effect of gene deletion of COX inhibition on plasma methylarginines. 
Methylarginines (ADMA, L-NMMA and SDMA) and creatinine in the plasma of wild-type, COX-1-/-, COX-2-/- 
(p-values by Kruskal-Wallis with Dunn’s post-hoc test) and IP-/- mice and wild type mice treated with vehicle 
or parecoxib fed a normal or a high salt diet (p-values by Mann-Whitney U-test).
!
 ADMA (µM) L-NMMA (µM) SDMA (µM) Creatinine 
(fold change) 
Wild-type  0.28 ± 
0.02 
0.070 ± 
0.01 
0.24 ± 
0.02 
1.00 ± 
0.04 
COX-1-/- 0.86 ± 
0.26 
(p=0.16) 
0.085 ± 
0.01 
(p=0.99) 
0.63 ± 
0.14 
(p=0.09) 
0.89 ± 
0.05 
(p=0.46) 
COX-2-/- 3.36 ± 
1.16* 
(p<0.01) 
0.38 ± 
0.11* 
(p=0.02) 
1.25 ± 
0.90 
(p>0.99) 
1.53 ± 
0.18* 
(p=0.01) 
 
Wild type normal 
salt; vehicle 
0.41 ± 
0.044 
0.27 ± 
0.079 
N/A N/A 
Wild type normal 
salt; parecoxib 
0.86 ± 
0.13* 
(p<0.01) 
1.19 ± 
0.26* 
(p=0.02) 
N/A N/A 
     
Wild type high 
salt; vehicle 
0.73 ± 
0.14 
 
0.78 ± 
0.17 
 
N/A N/A 
Wild type high 
salt; parecoxib 
1.12 ± 
0.10 
(p=0.18) 
0.75 ± 
0.07 
(p=1.00) 
N/A N/A 
 
IP+/+ 2.93 ±!
0.12 
0.30 ± 
0.04 
1.74 ± 
0.18 
1.0 ± 
0.04 
IP-/- 4.11 ± 
0.11* 
(p<0.01) 
0.11 ± 
0.02* 
(p<0.01) 
1.88 ± 
0.31 
(p=0.44) 
1.85 ± 
0.29* 
(p<0.01) 
= .007)
= .005)
(p=0.0 02) = . 02) (p=0.0 06)
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